Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

AlvotechNASDAQ: ALVO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 330.28M shares rose 17.4% year over year, ahead of the +6.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.4% holds above the trailing-twelve-month pace of +6.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
330.28M+18.3% QoQ
Last fiscal yearDec 2025
279.19M+4.2% YoY
LTMMar 2026
297.74M+6.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.4%——
1 year+4.2%——
3-year CAGR+12.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
279.19M USD
Year-over-year change
+4.2%
4-year CAGR
+72.9%

Weighted Avg Shares vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's LTM Mar 2026 weighted avg shares of 297.74M shares is the 4th highest of the 11 companies compared; the peer median is 125.26M shares.
  • Its year-over-year change of +6.2% is the highest of 11, against a peer median of +0.9%.
  • Over three fiscal years its annual growth of +12.2% compares with a peer median of +0.5%.
ALVO Competitors Peer median
Weighted Avg Shares for ALVO and competitors
Company Period LTM YoY 3-year CAGR
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20261.15B +1.5%+1.2%
AMGNAmgen Inc.LTM Jun 2026539.25M +0.2%+0.0%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026315.69M +1.5%+27.6%
ALVOAlvotechLTM Mar 2026297.74M +6.2%+12.2%
OGNOrganon & Co.LTM Sep 2026261.44M +1.0%+0.7%
BIIBBiogen Inc.LTM Jun 2026147.05M +0.9%+0.3%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026103.48M -3.2%-0.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202646.16M -4.6%-1.3%
HROWHarrow Health, Inc.LTM Mar 202636.98M +3.5%+10.2%
COLLCollegium Pharmaceutical, Inc.LTM Mar 202631.79M -1.1%-2.1%
ETONEton Pharmaceuticals, Inc.LTM Mar 202626.99M +3.1%+2.3%
Peer median (excluding ALVO) 125.26M+0.9%+0.5%

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.77M83.03M91.43M489.68M586.32M
Cost of Revenue064.1M160.86M185.31M235.56M
Gross Profit36.77M18.93M(69.42M)304.37M350.76M
Gross Margin100.0%22.8%-75.9%62.2%59.8%
Research & Development191.01M180.62M210.83M171.31M184.19M
Selling, General & Admin84.13M186.74M73.04M61.45M90.95M
Operating Expenses272.23M365.38M285.44M234.73M272.56M
Depreciation & Amortization18.2M20.41M24.21M31.3M37.85M
EBITDA(18.03M)(439.8M)(493.67M)(32.28M)323.39M
EBITDA Margin-49.0%-529.7%-539.9%-6.6%55.2%
Operating Income(235.46M)(346.44M)(354.86M)69.64M78.21M
Operating Margin-640.3%-417.3%-388.1%14.2%13.3%
Interest Income19K912K4.82M4.62M198.49M
Interest Expense112.97M91.44M134.82M157.6M149.19M
Other Income / Expenses86.26M(205.21M)(296.19M)(287.21M)58.14M
Income Before Tax(149.2M)(551.65M)(651.05M)(217.56M)136.35M
Pre-Tax Margin-405.7%-664.4%-712.0%-44.4%23.3%
Income Tax Expense(47.69M)(38.07M)(99.32M)14.3M108.43M
Net Income(101.5M)(513.58M)(551.73M)(231.86M)27.92M
Net Margin-276.0%-618.6%-603.4%-47.3%4.8%
EPS (Basic)(3.25)(2.60)(2.43)(0.87)0.10
EPS (Diluted)(3.25)(2.60)(2.43)(0.87)0.10
Weighted Avg Shares31.25M197.72M227.26M267.92M279.19M
Weighted Avg Shares (Diluted)31.25M197.72M227.26M267.92M279.19M

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.